Kelley Ross
Family · Spencer, WVNPI 1306084728
Payments from drug & device makers
Across 76 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$297
- AstraZeneca$250
- Dexcom, Inc.$152
- Merck$94
- Pfizer$67
- GSK$67
- plus $504 from 18 others
What the payments were for
- Food & beverage$1,432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $297 |
| AstraZeneca | 16 | $250 |
| Dexcom, Inc. | 8 | $152 |
| Merck | 5 | $94 |
| Pfizer | 3 | $67 |
| GSK | 4 | $67 |
| Amgen | 3 | $59 |
| Verona Pharma, Inc. | 3 | $51 |
| Novartis | 3 | $50 |
| Boehringer Ingelheim | 3 | $48 |
| Lilly USA, LLC | 3 | $45 |
| Abbott | 2 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $29 |
| Averitas Pharma Inc. | 1 | $25 |
| Organon | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Harmony Biosciences LLC | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Bioventus LLC | 1 | $13 |
| Novo Nordisk | 1 | $12 |
How this compares
$1,432 in reported general payments places this provider in the 70th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $78,184 |
| MounjaroTirzepatide | 44 | $70,683 |
| JardianceEmpagliflozin | 55 | $62,370 |
| RybelsusSemaglutide | 19 | $44,182 |
| XareltoRivaroxaban | 30 | $38,891 |
| EliquisApixaban | 25 | $37,966 |
| JanuviaSitagliptin Phosphate | 35 | $33,927 |
| TrulicityDulaglutide | 24 | $28,869 |
| InvokanaCanagliflozin | 14 | $19,223 |
| NeurontinGabapentin | 11 | $15,995 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,776 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $7,756 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,868 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,919 |
| MyrbetriqMirabegron | 11 | $5,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $12 | $122,36675 claims |
| Lilly USA, LLCMounjaro, Trulicity | $45 | $99,55168 claims |
| Boehringer IngelheimJardiance | $48 | $62,37055 claims |
| PfizerEliquis | $67 | $37,96625 claims |
| MerckJanuvia | $94 | $33,92735 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $250 | $18,53249 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $67 | $12,78728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,507 family providers in West Virginia.
Other family in Spencer
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.